

(a), a step of measuring the protein level of PTEN.

【Claim 14】

The method of claim 11, further comprising, before step (a), the steps of:

5 (a) detecting in a sample the presence or absence of a variant of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in a sample; and

(b) when the variant is present, selecting a phosphoinositide 3-kinase α (PI3K α) inhibitor as the patient-specific therapeutic agent.
10

【Claim 15】

The method of claim 14, wherein the variant of PIK3CA is selected from the group consisting of P140R, I381M, E453K, E542K, E545K, and H1047R in PIK3CA.

15 **【Claim 16】**

The method of claim 14, wherein the phosphoinositide 3-kinase alpha (PI3K α) inhibitor is selected from the group consisting of HS-173, Alpelisib (BYL719), CH5132799, Gedatolisib (PF-05212384, PKI-587), PIK-75, A66, and YM201636.

20 **【Claim 17】**

The method of claim 11, wherein the solid cancer is selected from the group consisting of stomach cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, renal cell cancer, breast cancer,